Evidence map›Paper›PMID 34857030›Full record

ArticleJournal of hematology & oncology2021

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas.

S Verbeke, R Perret, V Chaire, E Richard, V Velasco, F Giles, L Cavalcante, A Italiano

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

S VerbekeSarcoma Unit, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France.
R PerretDepartment of Pathology, Institut Bergonié, Bordeaux, France.
V ChaireSarcoma Unit, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France.
E RichardINSERM, U1218, Bordeaux, France.
V VelascoDepartment of Pathology, Institut Bergonié, Bordeaux, France.
F GilesActuate Therapeutics, Fort Worth, TX, USA.
L CavalcanteActuate Therapeutics, Fort Worth, TX, USA.ORCID http://orcid.org/0000-0002-9676-0789
A ItalianoSarcoma Unit, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France. a.italiano@bordeaux.unicancer.fr.ORCID http://orcid.org/0000-0002-8540-5351
Inserm · FRInstitut Bergonié · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soft tissue sarcoma (STS) is a predominantly fatal rare malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies. Its therapeutic relevance in STS is unknown. We analyzed the prognostic impact of GSK-3β gene and protein expression in two independent cohorts of patients with STS. We then treated STS cell lines and mice xenografts with a novel GSK-3 inhibitor 9-ING-41 alone or in combination with chemotherapy. We demonstrated that 9-ING-41 treatment induced significant STS cells apoptosis and was synergistic in vivo when combined with chemotherapy. Mechanistically, 9-ING-41 induces significant apoptosis of STS cells via suppression of NF-κB-mediated X-linked inhibitor of apoptosis protein (XIAP) expression. These data support the inclusion of patients with STS in clinical studies of 9-ING-41 alone and in combination with chemotherapy.

Indexed as

AnimalsApoptosisCell Line, TumorGlycogen Synthase Kinase 3 betaHumansMiceProtein Kinase InhibitorsSarcomaGlycogen Synthase Kinase 3 betaProtein Kinase Inhibitors9-ING-41Glycogen synthase kinase 3βSoft tissue sarcomas

Identifiers

PMID34857030
PMCPMC8641200
OpenAlexW3215764252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.